Kathleen B. Fig
Associate Director, Cell Therapy Trade & Distribution @Bristol Myers Squibb
Signup · Get unlimited contacts
WORK HISTORY
Associate Director, Cell Therapy Trade & Distribution @Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. US Value, Access & Payment: CAR-T Trade & Distribution ABECMA® (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells. BREYANZI® (lisocabtagene maraleucel) is a prescription medicine used to treat large B cell lymphoma, a type of non-Hodgkin lymphoma, when: your first treatment has not worked or your cancer returned within a year of your first treatment OR your first treatment has not worked or your cancer returned after the first treatment, and you are not eligible for hematopoietic stem cell transplantation because of medical conditions or age OR two or more kinds of treatment have not worked or stopped working. BREYANZI is made from your own white blood cells, which have been genetically modified to recognize and attack your lymphoma cells.
EDUCATION
Texas A&M University
BS, Bioenvironmental Sciences; Plant Pathology & Microbiology
SKILLS
ABOUT KATHLEEN B. FIG
Strategic Leader with thirteen years of forward-thinking business development experience…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.